0000000000462645

AUTHOR

R. Totaro

showing 2 related works from this author

A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple s…

2016

Abstract Introduction Depression and anxiety are common among patients with multiple sclerosis (MS) and are frequently present at the time of MS diagnosis. Methods POSIDONIA was a 12-month, observational, prospective study conducted in Italy to evaluate the impact of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosed MS. The Hospital Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) subscale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale – Revised (IES-R) were used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HDRS), HDRS-17, was used as a measure…

MalePsychometricsAnxietyHospital Anxiety and Depression Scale0302 clinical medicineImmunologic FactorMultiple sclerosis Disease-modifying treatment Emotional burden Anxiety DepressionMultiple SclerosiDisease-modifying treatment030212 general & internal medicineProspective StudiesProspective cohort studyDepression (differential diagnoses)DepressionMiddle AgedPsychiatric Status Rating ScaleTreatment OutcomeItalyNeurologyAnxietyFemaleSettore MED/26 - Neurologiamedicine.symptomPsychologyPsychometricHumanAdultmedicine.medical_specialtyMultiple SclerosisMood DisorderPsychometricsAdolescentLogistic Model03 medical and health sciencesYoung AdultRating scalemedicineHumansImmunologic FactorsAgedPsychiatric Status Rating ScalesMood Disordersmedicine.diseaseProspective StudieLogistic ModelsMood disordersPhysical therapyEmotional burdenObservational studyNeurology (clinical)030217 neurology & neurosurgery
researchProduct

Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving…

2011

Abstract Background Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring of multiple sclerosis (MS). In clinical trials, MRI has been found to detect treatment effects with greater sensitivity than clinical measures; however, clinical and MRI outcomes tend to correlate poorly. Methods In this observational study, patients (n = 550; 18-50 years; relapsing-remitting MS [Expanded Disability Status Scale score ≤4.0]) receiving interferon (IFN) β-1a therapy (44 or 22 µg subcutaneously [sc] three times weekly [tiw]) underwent standardized MRI, neuropsychological and quality-of-life (QoL) assessments over 3 years. In this post hoc analysis, MRI outcomes and corre…

MalePathologyNeurologyDiseaseRelapsing-RemittingNeuropsychological Testslcsh:RC346-4290302 clinical medicineRelapsing-Remitting Multiple Sclerosi030212 general & internal medicine10. No inequalitymedicine.diagnostic_testBrainGeneral MedicineMagnetic Resonance Imaging3. Good healthFemaleSettore MED/26 - NeurologiaRadiologyNeurosurgeryMagnetic Resonance Imaging; Neuroimaging; Immunologic Factors; Dose-Response Relationship Drug; Humans; Brain; Interferon-beta; Quality of Life; Multiple Sclerosis Relapsing-Remitting; Cognition Disorders; Adult; Neuropsychological Tests; Female; MaleDrugInterferon beta-1aResearch ArticleAdultmedicine.medical_specialtyMultiple SclerosisClinical NeurologyNeuroimagingDose-Response Relationship03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingNeuroimagingmedicineImmunologic FactorsHumansNeurochemistrylcsh:Neurology. Diseases of the nervous systemDose-Response Relationship Drugbusiness.industryMultiple sclerosisMagnetic resonance imagingBrain Magnetic Resonance ImagingInterferon-betamedicine.diseaseClinical trialBrain Magnetic Resonance Imaging; Relapsing-Remitting Multiple Sclerosis; Interferon beta-1aQuality of LifeNeurology (clinical)businessCognition Disorders030217 neurology & neurosurgery
researchProduct